Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Radiotherapy
100%
Targeted Therapy
100%
Everolimus
100%
Randomized Phase II Trial
100%
Diffuse Intrinsic Pontine Glioma
100%
95% Confidence Interval
100%
Erlotinib
60%
Dasatinib
60%
Overall Survival
40%
MTOR Inhibitor
40%
Median Overall Survival
40%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
40%
Hazard Ratio
20%
Treatment Discontinuation
20%
Multivariate Analysis
20%
Tumor
20%
Strong Predictor
20%
Worse Prognosis
20%
Treatment Allocation
20%
Phase II Trial
20%
Immunohistochemical Markers
20%
Mammalian Target of Rapamycin (mTOR)
20%
TP53 mutation
20%
Prognostic Biomarker
20%
Temozolomide
20%
Long-term Survivors
20%
Poor Survival
20%
Gastrointestinal Side Effects
20%
RNA Sequencing (RNA-seq)
20%
Exclusion Criteria
20%
Biopsy-proven
20%
Receptor Overexpression
20%
Tumor Profiling
20%
Whole Exome Sequencing
20%
PTEN Loss
20%
Structural Chromosomal Aberrations
20%
Therapeutic Biomarkers
20%
Pediatric Tumors
20%
Skin Side Effects
20%
Ocular Adverse Events
20%
Multi-targeted Tyrosine Kinase Inhibitor
20%
Independent Data Monitoring Committee
20%
Medicine and Dentistry
Targeted Therapy
100%
Everolimus
100%
Pontine Glioma
100%
Radiation Therapy
100%
Biological Marker
80%
Overall Survival
80%
Erlotinib
60%
Dasatinib
60%
Mammalian Target of Rapamycin Inhibitor
40%
Biopsy Technique
40%
Neoplasm
20%
Arm
20%
Hazard Ratio
20%
Gastrointestinal Distress
20%
Tyrosine-Kinase Inhibitor
20%
Mammalian Target of Rapamycin
20%
Epidermal Growth Factor Receptor Kinase Inhibitor
20%
Epidermal Growth Factor Receptor
20%
Temozolomide
20%
Chromosome Aberration
20%
Tumor
20%
RNA Sequence
20%
Pediatric Cancer
20%
Multivariate Analysis
20%